

Asian Society of Gynecologic Oncology

NEWS LETTER

Vol. 2

1. Message from the President (Hee-Sug Ryu)
2. Welcome Message (Seung-Cheol Kim)
3. Message from the President of KSGO (Young-Tak Kim)
4. Academic Program Guide (Jae-Weon Kim)
 - Program at a glance
5. ASGO 2017 Biennial Meeting Summary (Daisuke Aoki)
6. Manuscripts of New Council Members
 - Rongyu Zang
 - David Tan
7. ASGO 2019 Organizing Committee
8. Other Informations
 - JGO Poster
 - ASGO 2018 Membership Guide
 - ASGO 5th Int'l Workshop Poster
 - ASGO 6th Biennial Meeting Poster

Message from the President



Dear Colleagues and Friends,

It is a great pleasure for me to give a Presidential message of the 2nd Newsletter of Asian Society of Gynecologic Oncology (ASGO) on behalf of all members of ASGO.

In the early 2000s, some doctors in Japan and Korea discussed the need for an Asian gynecological cancer meeting. Since then, the ASGO inaugural

meeting was held in Seoul in 2008, so 2018 is the 10th anniversary of ASGO's founding. Thanks to the founders of the Society, ASGO has made tremendous progress despite its 10 year short history.

During the last 10 years, five ASGO meetings and four workshops have been successfully held in Korea and Japan. It has been good memories to discuss and share the progress of new developments in treating and caring for gynecologic cancer patients in Asian countries, and to deepen friendship with old friends and make new friends.

In particular, the 5th ASGO Biennial Meeting 2017 in Tokyo was extremely successful. We had lectures on topics in a variety of fields from distinguished speakers from Asia and around the world. I am confident that the conference would contribute to improving patient outcomes in our field in Asia.

However, a lot of work is still waiting for us, because Asia not only has the largest number of population but also gynecologic cancer patients in the world.

The official journal of ASGO, Journal of Gynecologic Oncology (JGO) is one of the leading journals in gynecologic oncology in the world with its impact factors reaching 3.14 in 2016. I am deeply grateful to the editorial board members who are constantly striving to maintain the highest quality journal, especially editor-in-chief, Prof. Jae-Won Kim.

I sincerely encourage gynecologists of Asia to join as ASGO members and submit valuable manuscripts to the JGO.

I am very happy to announce one of the key decisions of the 13th Council meeting held at Tokyo during the 5th Biennale in December 2017 to continue the Society's agenda forward, which is to hold meetings across

Asia outside Japan and Korea for the first time (From Workshop 2020 and Biennale 2021). I will make this change an opportunity for the society to expand and develop, and I would like to ask all members to cooperate with this change.

I am convinced that the Society has contributed to improving the results of gynecologic cancer patients in Asia, which is ASGO's mission and vision. However, it is still not enough in some areas of Asia. In particular, I think there should be more educational programs for young doctors to achieve the purpose of the society. To this purpose, we had an ASGO session at the 25th Asian & Oceanic Congress of Obstetrics and Gynecology (AOCOG) held in Hong Kong in June 2017, as well as sending expert professors to give educational lectures for domestic conferences in various countries.

I also want to strengthen the relationship with our sisterhood societies such as AOFOG, IGCS, ESGO and SGO. Establishing partnerships with these societies help us to become a truly global society devoted to improving the outcomes of gynecologic cancer patients in Asia. ASGO will make a joint

effort to support relevant international societies in the future.

Finally, on behalf of ASGO, I strongly encourage you to participate in the following upcoming meetings in Korea; the 5th Workshop and the 6th Biennial meeting of ASGO. I firmly believe that both meetings will be an opportunity for Asian doctors to improve their knowledge of this area and to allow all participants to have a broader view of gynecologic cancers.


I hope that the ASGO will play a leading role in creating environment of systematic research, educational and care for all patients suffering from gynecologic cancers in Asia.

"Toward the best care for the gynecologic cancer patients in Asia"

Hee-Sug Ryu, MD, PhD

*President, Asian Society of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology,
School of Medicine, Ajou University*

Welcome Message



Dear Friends and Colleagues,
You are cordially invited to the 5th ASGO workshop hosted in Suwon, South Korea.

It is my great pleasure and honor to be able to personally extend you an invitation to the 5th ASGO workshop. This year, we are expecting more than 300 clinicians, researchers, and doctors, united with a deep common interest in the research, prevention, and clinical management of gynecological cancers to join us for the workshop. I sincerely hope you can partake in the experience.

My mission is to ensure that our members have a meaningful and productive workshop; that means not only providing you with quality educational programs, but also presenting you with the opportunity to build strong partnerships with other members of ASGO. As Helen Keller once said, "Alone we can do so little; together we can do so much." With this opportunity, I hope we can become the foundation of a united force that will

bring academic and clinical developments forward to help those affected by gynecological cancer.

The venue for this meeting is located in Suwon(Ajou University Hospital), which can be easily accessed from two airports (Kimpo or Incheon Airport). Moreover, Suwon is a very historical place in terms of Korean History and has a perfectly preserved old fortress which is now listed as a UNESCO World Heritage. I hope you also enjoy sightseeing around Suwon City.

This year, the ASGO Workshop will take place in SUWON, KOREA. I am looking forward to seeing you soon.

Sincerely yours,

Seung-Cheol Kim, MD, PhD

*Chairman, Organizing Committee of ASGO 5th Int'l Workshop
Professor, Division of Gynecologic Oncology
Ewha Womans University Cancer Center for Women*

Message from the President of KSGO



The 'Workshop for Young Gynecologic Oncologist' was first organized in 2008 to encourage young doctors in gynecologic oncologic fields to promote their research activities and to share update knowledge.

This forum provides a platform to communicate on the issues chosen by the young doctors who are participating in the workshop. At this 12th workshop recent development in radiation oncology and surgical techniques will be presented with introduction of novel clinical trials.

I am happy to hold the meeting in conjunction with ASGO Workshop this year that would bring more participants from Asian region to join the session. This will also provide Korean young doctors to have good opportunities to

communicate and share knowledge with foreign delegates.

The goal of ASGO is to develop knowledge, skills, and professional network, ultimately to contribute to the women's health in the needy countries and regions. To achieve this, ASGO should enhance its relations and partnership with global organizations and national societies broadening its scope.

As a president of Korean Society of Gynecologic Oncology I welcome all participants, especially young scientist to both workshops and hope to share fruitful results and wonderful memories in Korea.

Prof. Young-Tak Kim

*President of KSGO
Professor, Department of Obstetrics and Gynecology
University of Ulsan, Asan Medical Center, Seoul, Korea*

Academic Program Guide



Dear Colleagues, On behalf of the Organizing Committee it is our great pleasure to invite you to join the Asian Society of Gynecologic Oncology (ASGO) 5th International Workshop on Gynecologic Oncology to be held from August 24-25, 2018 in the historic and cultural city of Suwon, Korea. ASGO 5th Workshop 2018 is being held in collaboration with the Korean Society of Gynecologic Oncology (KSGO).

Following the tradition of previous meetings, ASGO 5th International Workshop 2018 will provide you with the opportunity to learn about the latest clinical advances as well as international developments in research, practice and treatment for the best care of women with gynecological cancer.

The ASGO International Workshop 2018 in conjunction with the KSGO Workshop for Young Gynecologic Oncologists offers a unique program that covers the latest, cutting edge information including innovative developments in surgery, chemotherapy/targeted agents, radiotherapy,

and pathology. Translational aspects will be updated and developments in targeted therapies highlighted. The Workshop will also introduce guidelines for early career researchers, clinical trial updates in Asia and discuss the latest research trends.

World-class experts in gynecological oncology have organized the scientific program that will cover a broad range of topics. We have covered various topics, especially in recent issues including minimally invasive surgery in cervical cancer, target agent updates, HIPEC, and surgical techniques for gynecologic cancers. The film session will give us the opportunity to learn surgical techniques, exchange ideas, form new and maintain existing friendships.

We hope that this Workshop will be a time to share the latest knowledge and to promote the unity of our members.

Jae-Weon Kim, MD, PhD

*Chair, ASGO 5th Workshop 2018 Scientific Program Committee
Professor, Department of Obstetrics and Gynecology
Seoul National University College of Medicine*

Program at a glance

Time	August, 24 (Fri)			August, 25 (Sat)				
	Day 1			Day 2				
Place	Auditorium (ASGO Session)	Small Assembly Hall (KSGO Session)	Lobby	Auditorium (ASGO Session)	Small Assembly Hall (KSGO Session)	Lobby		
8:00	Registration			Registration				
	Opening Ceremony(08:30-08:40)							
9:00	[A-1] Cervical Cancer (08:40-10:20)		Poster display & Exhibition	[A-5] A Guide for Early Career Researchers (08:30-10:10)	[K-5] Clinical Trials in Asia (08:30-10:10)	Poster display & Exhibition		
10:00	Coffee Break (10:20-10:40)			Coffee Break(10:10-10:30)				
11:00	[A-2] Epithelial Ovarian Cancer (10:40-12:20)	[K-1] Radiation Oncology for Gynecologic Cancer * Korean(10:40-11:30)		[A-6] Junior Session(Oral-1) (10:30-12:10)	[K-6] Junior Session(Oral-2) (10:30-12:10) * Korean			
12:00		[K-2] Gynecologic Pathology (11:30-12:20)						
	Sponsored Session(12:20-12:40)			Sponsored Session(12:10-12:30)				
13:00	Lunch (12:40-13:40)			Lunch (12:30-13:10)				
14:00	[A-3] Guidelines & Position Statement (13:40-15:20)	[K-3] Surgical Technique (13:40-15:20)		[A-7] Endometrial Cancer (13:10-14:50)	[K-7] How to Care Well BRCA Mutation Carriers? (13:10-14:30) * Korean			
15:00	Sponsored Session(15:20-15:40)			Closing Ceremony (14:50-15:00)				
	Coffee Break(15:40-16:00)							
16:00	[A-4] Chemotherapy/Targeted Agents and Beyond (16:00-17:40)	[K-4] Film Session (16:00-17:40)						
17:00								
18:00								
19:00	Banquet (Ramada Plaza Hotel)							

2017 ASGO Biennial Meeting Summary



The 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO) was held at Otemachi Sankei Plaza in Tokyo between 30th November and 2nd December, 2017. I, as a congress president, would like to express my sincere appreciation to the organizing committee, all ASGO council members and every participant, especially young doctors from abroad. With their support, we witnessed the great success of this Biennial Meeting a total of 588 attendees from 18 countries all over the world (Table 1, from ASGO meeting report, <https://doi.org/10.3802/jgo.2018.29.e33>).

Table 1. Number of participants by country

Country	Number	Presentation				Total
		Lecture	Oral	Poster	Film	
Japan	270	60	20	68	12	160
Taiwan	68	4	4	21	0	29
South Korea	67	22	6	13	2	43
Thailand	48	1	4	12	1	18
Philippines	35	1	1	2	0	4
Indonesia	30	1	2	16	0	19
China	34	6	10	15	1	32
Hong Kong	9	2	0	2	0	4
Singapore	9	2	1	2	0	5
India	5	2	1	1	1	5
Israel	1	0	0	1	0	1
Malaysia	3	1	0	1	0	2
USA	3	1	0	0	0	1
France	2	1	0	0	0	1
Australia	1	1	0	0	0	0
Denmark	1	1	0	0	0	0
Nepal	1	0	1	0	0	1
United Kingdom	1	0	0	0	0	0
Total	588	106	50	154	17	325

Of the first day programs, there was a session of extensive and robotic surgery, which was one the most interesting sessions to young doctors. The session of extensive and robotic surgery consisted of three parts: 1) robotic surgery for gynecologic cancer, 2) robotic surgery for pelvic side wall tumors

in gynecologic cancer and 3) extensive surgery and robotic surgery for gynecologic oncology. All contents were actually from their research results and for sure updated my knowledge in the field of robotic surgery.

Of the second day programs, four sessions for the immune system and gynecological cancers were lectured: 1) PD-1 signal inhibitors for gynecologic cancers: future perspectives, 2) combination of therapeutic HPV DNA vaccine with radiation and immune modulators in HPV associated tumor, 3) immunologic profiles as potential biomarkers for predicting the outcome of ovarian cancer patients and 4) reversal of immunosuppression in ovarian cancer microenvironment by targeting NF- κ B-IL6/IL8 signal and its clinical application. Immune system was thought relatively complicated. However, I expect it was much more getting closer to many participants who listened to the lectures because most of the speakers tried to talk about the association of immune system and gynecologic cancers at the level of molecules.

The last day programs began with invited lectures, which was followed by update of endometrial cancer. Two topics of the invited lectures included: 1) update on clear cell carcinoma of ovary and 2) role of PARP inhibitors in ovarian cancer.

Last but not the least, not only surgical film exhibition and poster exhibition but also various social programs (Figure 1, from ASGO meeting report, <https://doi.org/10.3802/jgo.2018.29.e33>) were very beautiful and fantastic. I hope we all attained our academic and social goals through this meeting. ASGO will continue to work toward a goal, to enrich our research on gynecologic oncology and education programs for young doctors.

Daisuke Aoki, MD, PhD

*Congress President of ASGO 5th Biennial Meeting
Professor, Department of Obstetrics and Gynecology
Keio University School of Medicine*



Figure 1. Scenes of a banquet welcoming the participants (December 1, 2017, Royal Park Hotel, Tokyo)

Manuscripts of New Council Members

Ovarian Cancer Management: A Challenged Task in China



It's my great honor to be selected as a new council member of Asian Society of Gynecologic Oncology (ASGO). I am succeeded to Dr Zheyi Cao, the founder-president of Chinese Society of Gynecologic Oncology (CSGO) from 2004-2009. He is also the founder-member of ASGO. Another council member of ASGO from China is Dr Chunlin Chen at Beijing.

In China, ovarian cancer remains the leading cause of death in urban women with gynecological cancers. The incidence of ovarian cancer was 6.3 per 100 000 women in 2015 around the whole country (Chen W, et al. CA Cancer J Clin 2016; 66:115-32), and 5-yr. survival was 39.1%, with 0.4% decreased in 2012-15 when compared with that in 2009-11 (Zeng H, et al. Lancet Glob Health 2018;6:e555-67).

Most of the Chinese cancer centers are centralized in the management of ovarian cancer, with the volume over 200 cases per year, but lack of well training in radical surgery was quite common for gynecologic oncological surgeons, so 5-yr. progression-free survival of stage IIIC and IV ovarian cancer ranged from 5% to 18% (Ren et al. BMC Cancer 2015;15:583).

Treatment of ovarian cancer is still a challenged task in China. As a council member of ASGO, I will focus on education and training of surgical skills, clinical practice, best understanding of radical surgery for ovarian cancer in young generation; communication and collaboration with other Asian countries. The symposium of Asian-Pacific Ovarian Cancer Laparotomy and Laparoscopic Operation (APOLLO) is a platform for Asian doctors specialized in ovarian cancer research. It was initiated on May of 2016 in Shanghai, and doctors from China, Korea and Japan were involved the activities (Figure 1).



Figure 1. The first surgical training program on ovarian cancer in China.

Attachment: Introduction of CSGO

The Chinese Society of Gynecologic Oncology (CSGO) is an organization comprised of researchers that is focused on the clinical and translational research, prevention, and treatment of gynecological cancer in China.

Since it founded in 2004, CSGO currently is the most influential society among Chinese Gynecological Oncologists, with members all over the country. The first President is Professor Zeyi Cao (2004-2009), and the second President is Professor Keng Shen (2009-2015). Professor Ding Ma has been the current President (2015-). The regular meetings have previously more than 1000 participators, in which the top runners of each national region gather.

The main tasks of CSGO includes as follows.

1. Guide the normalized treatment of Gynecologic Cancers in China, with every 2 years renewal.
2. Holding national scholar meetings with widely communication of precise research results to enrich the landscape on gynecologic cancer studies. CSGO will also strengthen the international communications (Figures 2).
3. Education and training programs for young researchers who specialize gynecologic oncology.
4. Promote multi-center clinical trials to drive towards high-level evidence-based medicine. There are 10 on-going trials including endometrial cancer, cervical cancer and trophoblastic tumor. Specifically, such as (1) Multi-center prospective randomized controlled study of postoperative adjuvant radiotherapy and chemotherapy for early stage cervical cancer, (2) Multi-center study of MTX and MTX combined with ACT-d in the treatment of low risk GTD, (3) Multi-center study of hysterectomy plus lymph node dissection in the treatment of early stage cervical cancer, (4) Multi-center study of adjuvant chemotherapy for patients with cervical cancer after radical hysterectomy, and so on.

Rongyu Zang, MD, PhD

Ovarian Cancer Program, Division of Gynecologic Oncology,
Department of Obstetrics and Gynecology, Zhongshan Hospital,
Fudan University, Shanghai, China



Figure 2. Recent meetings of CSGO

Gynecologic Oncology in Singapore: A Growing Problem



In Singapore, gynecological cancers are amongst the top ten most common cancers diagnosed in women. Furthermore, while the incidence of cervical cancers is falling, the incidence of ovarian and uterine cancers has been rising in the past few years. In fact, breast, colorectal and lung cancers had consistently been the top three ranking cancers in terms of Age-Standardised Incidence Rates (ASR) in women, until uterine cancer overtook lung cancer over the period of 2011 to 2015 to become the 3rd most common in Singapore, with ovarian cancer remaining in 5th place.




Fig 1: Ten Most Frequent Cancers in Females (%), 2011 – 2015
(source: <https://www.nrdo.gov.sg/publications/cancer>)

Formation of the Gynecologic Cancer Group Singapore (GCGS) in 2017

Many of the academic cancer centres in Singapore have already had a long history of participation in clinical trials for women with gynecological cancer. Unfortunately, however, a clinical network for collaborative research had long been lacking. In recognition of the growing incidence gynecological cancers, and the need to find better approaches to treat patients with these malignancies, physicians with specialist interests in the management of gynecological cancers from the private and public sector came together in 2017 to form the first clinical trials and research network dedicated to the study and advancement of gynecological cancer care in Singapore called the Gynecologic Cancer Group Singapore (GCGS).

The aims of the GCGS are:

- To create an open platform of individual professionals dedicated to the advancement and development of gynecological cancer care.
- To provide a platform for collaborative practice in constantly raising the standard of women's cancer care in Singapore in a consistent and evidence-based fashion.
- To provide a national platform for women's cancer research.
- To establish a forum for the exchange of ideas, information and intellectual discourse on women's cancer care.
- To engage industry partners in order to guide the direction of clinical and commercial development that is ultimately beneficial to the women in Singapore and the region.



- To promote communication with other relevant scientific and professional organizations.
- To improve women's cancer healthcare in Asia through the formation of a co-operative that openly shares and tracks clinical outcomes for research, process improvement and procedural development.



Fig 2: Inaugural Meeting of the Gynecologic Cancer Group Singapore (GCGS) on 19th Aug 2017

The current executive board members of GCGS are:

- President: Dr David Tan, Medical Oncologist, National University Cancer Institute Singapore (NCIS), National University Hospital (NUH)
- Vice-President: Dr Joseph Ng, Gynecologic Oncologist, National University Cancer Institute Singapore (NCIS), National University Hospital (NUH)
- Secretary: Dr Lim Yong Kuei, Timothy, Gynecologic Oncologist, KK Women's and Children Hospital (KKH)
- Treasurer: Dr Jeffrey Low, Gynecologic Oncologist, National University Cancer Institute Singapore (NCIS), National University Hospital (NUH)

The first GCGS meeting was held on 19th August 2018 at Shangri La Hotel Singapore where more than 30 Gynecologic Surgical Oncologists, Medical Oncologists and Radiation Oncologists, Pathologists and Specialist Cancer Nurses from KK Women's and Children Hospital (KKH), National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), Parkway Cancer Centre and Oncocare Cancer Centre (both at Mount Elizabeth Hospital), and Gleneagles Hospital Singapore, met up to discuss ideas for collaborative trials both nationally and internationally.

Following the formation of the group, the GCGS have also been accepted this year as a provisional member of Gynaecologic Cancer Intergroup (GCIG) and will be represented at the GCIG Annual meeting in Chicago in June 2018.

Ongoing clinical trials/ research studies being hosted by GCGS sites are as follows:

Title	NCT number	Status	Countries involved
A Multicentre Phase II randomised trial of MEDI4736 (DURVALUMAB) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA)	NCT03405454	Active	Singapore (GCGS) Australia (ANZGOG) Korea (KGOG)
Open-label, single-arm, phase 2 trial of regorafenib in recurrent ovarian clear cell carcinoma (NCC OV-01)	NCT02736305	Active	Singapore (GCGS)
Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO)	NCT02078544	Active	Singapore (GCGS)

Title	NCT number	Status	Countries involved
Phase Ib/Ia study to evaluate the safety and efficacy of the combination of anti-CA 125 monoclonal antibody, Oregovomab, and PD-1 inhibitor, Nivolumab, to treat recurrent EOCORION-01 (NCC OV-02)	NCT03100006	Active	Singapore (GCGS)
Phase II Study of Vinorelbine In Stem-A/C5-like Subtype Platinum Resistant Ovarian Cancer (VIP trial)	NCT03188159	Active	Singapore (GCGS) Australia (ANZGOG)
Phase I Study of Low Dose Whole Abdominal Radiation Therapy (LDWART) in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer With Predominant Non-visceral Abdominal Disease	NCT02545010	Active	Singapore (GCGS)
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc): A Randomized Phase II/III Trial of IV Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal	NCT01506856	Completed recruitment	Singapore (GCGS)

was immediately struck by the amicable atmosphere of the group and a keenness to work together to build on the past success of the society. From my early impressions, one can clearly see that there is tremendous potential for ASGO to continue to expand as a regional platform for research and education. It was also very heartening to see and hear the enthusiastic discussions and debates between both younger and older gynecologic cancer physicians during the oral and poster presentations throughout the ASGO 2017 conference. Our GCGS members certainly look forward to participating in and contributing to the next meeting in 2019. Furthermore, it is hoped that further investigator initiated multicentre/ multinational research studies can be developed by collaborating with other gynecologic cancer groups within ASGO. An example of this is the MOCCA (A Multicentre Phase II randomised trial of MEDI4736 (Durvalumab) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas) randomized phase 2 trial that is currently being carried out in collaboration between GCGS, the Korean Gynecologic Oncology Group (KGOG) and Australian and New Zealand Gynecologic Oncology Group (ANZGOG). This is an investigator initiated study with co-funding provided by Astra-Zeneca and the National Medical Research Council (NMRC) in Singapore. It is hoped that this trial will provide a model to develop and run future collaborative academic clinical studies between ASGO member countries, thus further empowering the value and scope of gynecological cancer research in the region.

David SP Tan

*Department of Haematology-Oncology,
National University Cancer Institute, Singapore*

As a group, we look forward to collaborating even more closely with other clinical trials networks within the Asia-Pacific region and we strongly feel that this initiative will be a crucial to addressing the most pertinent diagnostic and therapeutic challenges in gynecologic oncology for women in this part of the world.

Dr Chia Yin Nin steps down as the Singapore council member for ASGO



Dr. Chia Yin Nin

In December last year, at 5th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2017) in Tokyo, I formally took over from Dr Chia Yin Nin as the council representative for Singapore on the ASGO council. It was a real privilege to take over from Dr Chia who has been a dedicated, long serving member at the council, and was in fact one of the founding members of ASGO. Dr Chia was

formerly the deputy head of the Department of Gynecological Oncology and the head of the gynaecological cancer unit of the Department of Gynecological Oncology at the Kangar Kerbau Women's and Children's Hospital (KKH). She was also formerly the President for the Society of Colposcopy and Cervical Pathology of Singapore. Dr Chia also sits on the editorial board for the Journal of Gynaecologic Oncology. I would like to extend a heartfelt thank you to her on behalf of our gynecologic oncology community for her work throughout her tenure as an ASGO council member.

Role of Singapore in the future development of ASGO

Having been initiated into the council on the 1st of December at the Royal Park Hotel, I

ASGO 2019 Organizing Committee

ASGO President

Hee-Sug Ryu

ASGO Secretary General

Suk-Joon Chang

Organizing Committee Chair

Seung-Cheol Kim

Advisor

Soon-Beom Kang

Duk-Soo Bae

Joo-Hyun Nam

Young-Tak Kim

Scientific Program Committee

Jae-Weon Kim

Jong-Min Lee

Rongyu Zang

Finance Committee

Yong-Man Kim

Tae-Jin Kim

Seok-Ju Seong

International Relations Committee

Young-Tae Kim

Sang-Young Ryu

Chul-Min Lee

Planning Committee

Soo-Young Hur

Joong-Sub Choi

Sung-Yob Kim

Social Program Committee

Jae-Kwan Lee

Young-Han Park

Won-Deok Joo

Advertising Committee

Yoon-Soon Lee

Ki-Hyung Kim

Kwang-Beom Lee

Exhibition Committee

Seok-Mo Kim

Seob Jeon

Seung-Su Han

Publication Committee

Byoung-Gie Kim

Ju-Won Noh

Sok-Bom Kang

Secretary General

Yun-Hwan Kim

Dong-Hoon Suh

JGO

JOURNAL OF GYNECOLOGIC ONCOLOGY



ejgo.org
Mobile Web



Journal of Gynecologic Oncology

starts accepting manuscript submissions through



from the 1st of April 2018.

www.editorialmanager.com/JGynecolOncol

The old system will run in parallel with the new system until the end of reviews and revisions of manuscripts already in progress.

Contact us via email to jgo.editorial.office@gmail.com



Official Journal of the Asian Society of Gynecologic Oncology



Join 2018 Membership of ASGO

ASGO welcomes membership on year of 2018-you can renew your membership

The ASGO membership in 2018 should be renewed on our official website.

As a membership benefit, you can access to member only page,
meeting resources.

The annual membership dues are based on country tiers as per the classification of the World Bank

150 USD per year for high-income economies	50 USD per year for middle-income economies	25 USD per year for low-income economies
Japan, Hong Kong, Korea, Singapore, Taiwan, Qatar, Saudi Arabia, Slovenia, Kuwait, United Arab Emirates	Bhutan, China, India Indonesia, Malaysia, Lao, PDR, Philippines, Thailand, Turkey, Iran, Iraq, Vietnam	Afghanistan, Bangladesh, Cambodia, Korea, Dem. Rep. Kyrgyzstan, Myanmar, Nepal

To find more information of benefits, please visit website.

<http://www.asgoworkshop2018.com/>

If you have any Question about ASGO membership,
Please feel free to contact the secretariat,
asgo2019@aim-korea.com



www.asgoworkshop2018.com

ASGO WORKSHOP

ASGO 5th International Workshop on Gynecologic Oncology
in conjunction with
12th KSGO Workshop for Young Gynecologic Oncologists

Date: August 24th – 25th, 2018

Venue: Ajou University Hospital, Suwon, Korea

Secretariat of ASGO

#103-1106 ParkTower, 67 Seobinggo-ro, Yongsan-gu, Seoul 04385, Korea

Tel: +82-2-3452-1855 | Fax: +82-2-2192-3955 | E-mail: asgo2019@aim-korea.com

www.asiansgo.org



ASGO 2019

The 6th Biennial Meeting of Asian Society of Gynecologic Oncology

Date: October 10th–12th, 2019

Venue: Songdo Convensia,
Incheon, Korea

President of ASGO

Hee-Sug Ryu, MD, PhD
Ajou University

Organizing Chair

Seung-Cheol Kim, MD, PhD
Ewha Womans University

Secretariat of ASGO 2019 & ASGO Workshop

#103-1106 Park Tower, 67 Seobinggo-ro, Yongsan-gu, Seoul 140-904, Korea
Tel: +82-2-3452-1855 | Fax: +82-2-2192-3955 | E-mail: asgo2019@aim-korea.com

Supported by



Incheon
Metropolitan City



Incheon Tourism
Organization